Training in Translational ADRD Neuroscience (TITAN)

项目摘要/摘要 人口老龄化正在导致越来越多的阿尔茨海默氏症患者面临公共健康危机 疾病(AD)和相关痴呆症(ADRD)。距离FDA上一次批准这一产品已经超过15年了 一种治疗ADRD的新方法。继续过去十年在理解ADRD方面的戏剧性进展 病理生理学我们将需要重要的临床前和临床转化研究来带来候选人 将治疗方法转化为临床使用，并培育出足以遏制 阿德勒。这一成功的关键将是新一代ADRD科学家，特别是具有 设计和执行翻译研究所需的独特培训和技能。这种培训很少提供 通过传统的医学、临床心理学、基础科学或生物统计学课程。作为一名 结果，缺乏训练有素的ADRD翻译调查人员。此外，也没有足够的多样性 在目前活跃的ADRD翻译调查小组中，限制了独特的视角和团队 可能推动该领域走向关键解决方案的科学协同效应。 我们在这里提出了一项新的翻译ADRD研究培训计划，名为“翻译ADRD培训” 加州大学欧文分校神经科学(泰坦)。这项新的培训计划将广泛地 包括有前途的研究生和初级翻译科学家，如内科医生、临床 心理学家、流行病学家、生物统计学家、生物伦理学家和神经学家。我们已经组装了一个 杰出的、同样多样化的导师团队，他们将确保这一新培训计划的成功。 该计划将在ADRD翻译研究方面开发新的培训机会，同时还利用 UCI的大量科学和培训资源，包括NIA P30资助的阿尔茨海默病 研究中心(ADRC)，自2020年4月起包括一个研究教育部分， 目标相辅相成。同样，UCI临床与翻译科学研究所(ICTS)也是UCI的 NCATS资助的CTSA计划，提供可利用的协同培训选项，如K-Club， 负责任地举办研究研讨会，以及KL2资助机制。我们将从以下方面招聘不同的实习生 多学科专业以及来自全国代表性不足的种族和民族群体的个人， 残疾人、弱势背景的个人和妇女。

Project Summary/Abstract Population aging is leading to a public health crisis in the growing number of people affected by Alzheimer’s disease (AD) and Related Dementias (ADRD). It has been more than 15 years since the last FDA approval for a new treatment for ADRD. To continue the dramatic progress over the last decade in understanding ADRD pathophysiology we will require significant preclinical and clinical translational research to bring candidate therapies to clinical use and grow a therapeutic armamentarium sufficient to curb the public health impact of ADRD. Essential to this success will be a new generation of ADRD scientists, especially scientists with the unique training and skills necessary to design and perform translational research. This training is rarely provided through the traditional course of medical, clinical psychology, basic science, or biostatistical education. As a result, there is a dearth of well-trained ADRD translational investigators. Moreover, there is inadequate diversity among the current group of active ADRD translational investigators, limiting the unique perspectives and team science synergies that could propel the field toward critical solutions. We propose here a new training program in translational ADRD research titled “Training in Translational ADRD Neuroscience (TITAN)” at the University of California, Irvine (UCI). This new training program will be broadly inclusive of promising graduate students and junior translational scientists, such as medical doctors, clinical psychologists, epidemiologists, biostatisticians, bioethicists, and neuroscientists. We have assembled an outstanding and similarly diverse team of preceptors who will ensure the success of this new training program. The program will develop novel training opportunities in ADRD translational research while also leveraging the considerable scientific and training resources at UCI, including the NIA P30-funded Alzheimer’s Disease Research Center (ADRC), which since April 2020 includes a Research Education Component with complementary objectives. Similarly, the UCI Institute for Clinical and Translational Science (ICTS) is UCI’s NCATS-funded CTSA program that offers synergistic training options to be leveraged, such as the K-club, responsible conduct of research workshops, and KL2 funding mechanisms. We will recruit diverse trainees from multidisciplinary specialties as well as individuals from nationally underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds, and women.